81
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Ribonuclease Activity of the Peptides with Alternating Arginine and Leucine Residues Conjugated to Tetrathymidilate

, , , , &
Pages 885-890 | Received 02 Dec 2003, Accepted 23 Apr 2004, Published online: 23 Aug 2006
 

Abstract

RNA cleaving conjugates have been prepared by attachment of oligodeoxyribonucleotide TTTT to peptides containing arginine, leucine, proline and serine residues. The highest activity was displayed by the conjugates containing peptides with alternating arginine and leucine residues (LR)4G‐amide. Ribonuclease activity of the conjugates pep‐T4 decreases in the order T4‐(LR)4G > T4‐(LR)2G > T4‐(LLRR)2G > T4‐(LR)2PRLRG > S2R3‐Hmda‐T4 ≥ R5 ≠ (LR)3. According to CD spectra, the free peptide (LR)4G‐amide in water solution at neutral pH and physiological ionic strength has no pronounced secondary structure whereas conjugated to oligonucleotide it acquires a folding similar to α‐helix.

Acknowledgments

This work was supported by the grants from The Wellcome Trust (No. 063630), CRDF NO‐008‐X1 and a grant from the Ministry of Education of the Russian Federation under the auspices of the program “Fundamental investigations and high education” Y1‐B‐08‐08, RFBR No. 02‐04‐48664 and 03‐04‐06238, grant SS‐1384.2003.4, grant SB RAS for Interdisciplinary investigations and in Support of young scientists.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.